News
NICE breast cancer criteria missing patients, claims study
NICE's criteria to decide who is referred for further breast cancer risk assessment miss up to 95% of younger women who go on to develop the disease.
News
Pathos AI signs two cancer deals with Alphamab and AZ
Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.
News
Curium strikes $8bn deal to buy radiopharma rival Lantheus
Two players in the radiopharma sector, Curium and Lantheus, have agreed to merge and create an end-to-end player in diagnostics and therapeutics.
Oncology
Key lessons from EHA 2026: Translating evidence into impact
Across four days in Sweden, EHA 2026 offered a clear view of the future of blood cancer care.
News
Datroway joins Trodelvy for frontline TNBC in the EU
AstraZeneca and Daiichi Sankyo's Datroway enters the first-line triple-negative breast cancer market in the EU, taking on Gilead's Trodelvy.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
